Company intelligence
Camelot BioCapital
Bringing Innovative Treatment Modalities to Patients Suffering from Diseases with Limited Pharmacological Options
About Camelot BioCapital
Camelot is a venture platform focusing on biotech company creation. Our firm partners with inventors, research centers, and academic institutions to accelerate the development of novel therapeutic compounds. Leveraging deep industry relationships, including top scientific advisors, healthcare investment banks, CROs, and investors, we specialize in advancing early to mid-stage treatments through the FDA pipeline with the goal of delivering life-changing therapies to patients in need. Our investment focus is centered on pre-seed and seed-stage opportunities in oncology, autoimmune, and inflammatory disorders.
Verified activity
Signals from Camelot BioCapital
2 published signals
Capital & Finance
Camelot BioCapital reported eight deals up to $19 billion in CAR-T and in vivo CAR-T cell therapy, with zero of the eight showing a way to switch the cells off once they're in.
Reported by Camelot BioCapital
Capital & Finance
Camelot BioCapital reported that five China-origin licensing deals announced this year add up to $50.8 billion.
Reported by Camelot BioCapital